 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| 12» |
- EDP1503 / Evelo Biosci, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Metastases: Pembrolizumab and EDP1503 in Advanced Melanoma (clinicaltrials.gov) - Jul 31, 2024
P2, N=8, Active, not recruiting, Sponsor: University of Chicago
Suspended --> Active, not recruiting
- || EDP1815 / Evelo Biosci
Clinical, P2 data, Journal, Immunomodulating: A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis. (Pubmed Central) - May 30, 2024
P2
EDP1815 was well-tolerated with a placebo-like safety profile, and had meaningful efficacy outcomes in psoriasis, validating this novel immunomodulatory approach. https://www.clinicaltrials.gov/search?term=NCT04603027, identifier NCT04603027.
- || EDP1815 / Evelo Biosci
Clinical, Journal, Immunomodulating: Immunomodulating effects of the single bacterial strain therapy EDP1815 on innate and adaptive immune challenge responses (Pubmed Central) - May 15, 2024
P1
There was a lower influx of interleukin [IL]-1?, IL-6, IL-8, IL-10, interferon [IFN]-? and tumour necrosis factor in blister fluid of EDP1815-treated participants.
- EDP1503 / Evelo Biosci, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Pembrolizumab and EDP1503 in Advanced Melanoma (clinicaltrials.gov) - Jan 28, 2024
P2, N=8, Suspended, Sponsor: University of Chicago
and tumour necrosis factor in blister fluid of EDP1815-treated participants. Trial completion date: Nov 2023 --> Nov 2027 | Trial primary completion date: Nov 2023 --> Nov 2027
- |||||| EDP1815 / Evelo Biosci
Trial termination: A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials (clinicaltrials.gov) - Sep 7, 2023
P2, N=287, Terminated, Sponsor: Evelo Biosciences, Inc.
Trial completion date: Nov 2023 --> Nov 2027 | Trial primary completion date: Nov 2023 --> Nov 2027 Active, not recruiting --> Terminated; Parent Study (NCT05121480) did not meet the primary endpoint.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, EDP1815 / Evelo Biosci
Trial completion, Enrollment change: TACTIC-E: mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (clinicaltrials.gov) - Jul 31, 2023
P2/3, N=454, Completed, Sponsor: Cambridge University Hospitals NHS Foundation Trust
Active, not recruiting --> Terminated; Parent Study (NCT05121480) did not meet the primary endpoint. Recruiting --> Completed | N=1407 --> 454
- | EDP1815 / Evelo Biosci
Journal: Clinical translation of anti-inflammatory effects of Prevotella histicola in Th1, Th2, and Th17 inflammation. (Pubmed Central) - May 22, 2023
P1
These clinical effects occur without systemic exposure of EDP1815 or modification of the resident gut microbiota, and with placebo-like safety and tolerability. The breadth of these clinical effects of EDP1815, combined with its excellent safety and tolerability profile and oral administration, suggests the potential for a new type of effective, safe, oral, and accessible anti-inflammatory medicine to treat the wide range of diseases driven by inflammation.Clinical Trial Registration: EudraCT # 2018-002807-32; EudraCT # 2018-002807-32; NL8676; https://clinicaltrials.gov/ct2/show/NCT03733353; http://www.trialregister.nl.
- || EDP1815 / Evelo Biosci, EDP2939 / Evelo Biosci
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Evaluation of the Immunopharmacology of EDP1815 and EDP2939 (clinicaltrials.gov) - May 19, 2023
P1, N=38, Completed, Sponsor: Evelo Biosciences, Inc.
The breadth of these clinical effects of EDP1815, combined with its excellent safety and tolerability profile and oral administration, suggests the potential for a new type of effective, safe, oral, and accessible anti-inflammatory medicine to treat the wide range of diseases driven by inflammation.Clinical Trial Registration: EudraCT # 2018-002807-32; EudraCT # 2018-002807-32; NL8676; https://clinicaltrials.gov/ct2/show/NCT03733353; http://www.trialregister.nl. Recruiting --> Completed | N=72 --> 38 | Trial completion date: Apr 2023 --> Oct 2022 | Trial primary completion date: Apr 2023 --> Oct 2022
- ||| EDP1815 / Evelo Biosci
Enrollment closed, Trial completion date, Trial primary completion date: A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials (clinicaltrials.gov) - May 6, 2023
P2, N=287, Active, not recruiting, Sponsor: Evelo Biosciences, Inc.
Recruiting --> Completed | N=72 --> 38 | Trial completion date: Apr 2023 --> Oct 2022 | Trial primary completion date: Apr 2023 --> Oct 2022 Enrolling by invitation --> Active, not recruiting | Trial completion date: Feb 2024 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023
- EDP1503 / Evelo Biosci, Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Metastases: Pembrolizumab and EDP1503 in Advanced Melanoma (clinicaltrials.gov) - Apr 28, 2023
P2, N=8, Suspended, Sponsor: University of Chicago
Enrolling by invitation --> Active, not recruiting | Trial completion date: Feb 2024 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023 Trial primary completion date: Nov 2022 --> Nov 2023
- |||| EDP1815 / Evelo Biosci
Trial completion: A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis (clinicaltrials.gov) - Mar 30, 2023
P2, N=421, Completed, Sponsor: Evelo Biosciences, Inc.
Trial primary completion date: Nov 2022 --> Nov 2023 Active, not recruiting --> Completed
- | EDP1503 / Evelo Biosci
Phase classification, Checkpoint inhibition, Metastases: KEYNOTE-939: A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors (clinicaltrials.gov) - Mar 24, 2023
P1, N=69, Completed, Sponsor: Evelo Biosciences, Inc.
Active, not recruiting --> Completed Phase classification: P1/2 --> P1
- || EDP1815 / Evelo Biosci
Trial completion: Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms (clinicaltrials.gov) - Mar 24, 2023
P1, N=48, Completed, Sponsor: Evelo Biosciences, Inc.
Phase classification: P1/2 --> P1 Active, not recruiting --> Completed
- ||| EDP1815 / Evelo Biosci, EDP2939 / Evelo Biosci
New P1 trial: Evaluation of the Immunopharmacology of EDP1815 and EDP2939 (clinicaltrials.gov) - Jan 12, 2023
P1, N=72, Recruiting, Sponsor: Evelo Biosciences, Inc.
- | EDP1066 / Evelo Biosci
Journal: Impact of oral administration of single strain Lactococcus lactis spp. cremoris on immune responses to keyhole limpet hemocyanin immunization and gut microbiota: A randomized placebo-controlled trial in healthy volunteers. (Pubmed Central) - Dec 31, 2022
cremoris (EDP1066) on the immune response to keyhole limpet hemocyanin (KLH)...The clinical impact of these effects awaits further investigations. trialsearch.who.int, trial ID NL7519.
- ||| EDP1815 / Evelo Biosci
Enrollment change: A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials (clinicaltrials.gov) - Dec 19, 2022
P2, N=405, Enrolling by invitation, Sponsor: Evelo Biosciences, Inc.
trialsearch.who.int, trial ID NL7519. N=300 --> 405
- |||| EDP2939 / Evelo Biosci
New P2 trial: A study to investigate EDP2939 in healthy volunteers and participants with moderate psoriasis. (EUDRACT) - Dec 15, 2022
P2, N=146, Ongoing, Sponsor: Evelo Biosciences, Inc.
- ||| EDP1815 / Evelo Biosci
Enrollment closed: A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis (clinicaltrials.gov) - Nov 4, 2022
P2, N=405, Active, not recruiting, Sponsor: Evelo Biosciences, Inc.
N=300 --> 405 Recruiting --> Active, not recruiting
- ||| EDP1867 / Evelo Biosci
Trial completion, Enrollment change, Trial completion date: EDP1867-101: Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma (clinicaltrials.gov) - Oct 7, 2022
P1, N=52, Completed, Sponsor: Evelo Biosciences, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=96 --> 52 | Trial completion date: May 2022 --> Feb 2022
- EDP1815 / Evelo Biosci
Biomarker Evidence of Anti-inflammatory Effects of EDP1815 in a Phase 2 Psoriasis Clinical Trial (e-Poster Hall) - Aug 3, 2022 - Abstract #EADV2022EADV_1483;
- || EDP1815 / Evelo Biosci
Enrollment closed: Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms (clinicaltrials.gov) - Jul 29, 2022
P1, N=48, Active, not recruiting, Sponsor: Evelo Biosciences, Inc.
Active, not recruiting --> Completed | N=96 --> 52 | Trial completion date: May 2022 --> Feb 2022 Recruiting --> Active, not recruiting
- || EDP1815 / Evelo Biosci
Enrollment open, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms (clinicaltrials.gov) - Jul 21, 2022
P1, N=48, Recruiting, Sponsor: Evelo Biosciences, Inc.
Recruiting --> Active, not recruiting Completed --> Recruiting | N=36 --> 48 | Trial completion date: May 2022 --> Sep 2022 | Initiation date: Aug 2021 --> Jul 2022 | Trial primary completion date: May 2022 --> Sep 2022
- || EDP1815 / Evelo Biosci
Trial completion, Enrollment change: Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms (clinicaltrials.gov) - Jul 1, 2022
P1, N=36, Completed, Sponsor: Evelo Biosciences, Inc.
Completed --> Recruiting | N=36 --> 48 | Trial completion date: May 2022 --> Sep 2022 | Initiation date: Aug 2021 --> Jul 2022 | Trial primary completion date: May 2022 --> Sep 2022 Recruiting --> Completed | N=24 --> 36
- ||||| EDP1815 / Evelo Biosci
New P2 trial: A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials (clinicaltrials.gov) - Jun 30, 2022
P2, N=300, Enrolling by invitation, Sponsor: Evelo Biosciences, Inc.
- ||| EDP1815 / Evelo Biosci
Enrollment change, Trial completion date, Trial primary completion date: A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis (clinicaltrials.gov) - Jun 16, 2022
P2, N=405, Recruiting, Sponsor: Evelo Biosciences, Inc.
Recruiting --> Completed | N=24 --> 36 N=300 --> 405 | Trial completion date: Nov 2022 --> Apr 2023 | Trial primary completion date: Oct 2022 --> Mar 2023
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, EDP1867 / Evelo Biosci
Treatment with an orally delivered non-replicating, non-colonizing strain of Veillonella parvula resolves systemic inflammation in murine models of disease (Exhibit Hall; P539) - Apr 8, 2022 - Abstract #IMMUNOLOGY2022IMMUNOLOGY_1776;
These data demonstrate that EDP1867 can act as a new oral anti-inflammatory drug that is gut restricted and dependent on local immune recognition within the small intestine, to induce systemic anti-inflammatory effects. EDP1867 is currently in clinical development for treatment of inflammatory diseases.
- | EDP1867 / Evelo Biosci
Journal: Regulation of Peripheral Inflammation by a Non-Viable, Non-Colonizing Strain of Commensal Bacteria. (Pubmed Central) - Mar 29, 2022
Finally, we show that adoptively transferred T cells from EDP1867-treated mice inhibit inflammation induced in recipient mice. These results demonstrate that an orally-delivered, non-viable strain of commensal bacteria can mediate potent anti-inflammatory effects in peripheral tissues through transient occupancy of the gastrointestinal tract, and support the development of non-living bacterial strains for therapeutic applications.
- EDP1815 / Evelo Biosci
A phase 2 study investigating the effect of EDP1815, an orally-delivered, anti-inflammatory, gut-restricted commensal microbe in the treatment of mild and moderate plaque psoriasis (210A) - Mar 6, 2022 - Abstract #AAD2022AAD_1709;
- || EDP1867 / Evelo Biosci
Enrollment closed: EDP1867-101: Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma (clinicaltrials.gov) - Mar 2, 2022
P1, N=96, Active, not recruiting, Sponsor: Evelo Biosciences, Inc.
These results demonstrate that an orally-delivered, non-viable strain of commensal bacteria can mediate potent anti-inflammatory effects in peripheral tissues through transient occupancy of the gastrointestinal tract, and support the development of non-living bacterial strains for therapeutic applications. Recruiting --> Active, not recruiting
- |||| EDP1815 / Evelo Biosci
Enrollment open: A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis (clinicaltrials.gov) - Jan 24, 2022
P2, N=300, Recruiting, Sponsor: Evelo Biosciences, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| EDP1815 / Evelo Biosci
Trial completion: A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis (clinicaltrials.gov) - Jan 9, 2022
P2, N=225, Completed, Sponsor: Evelo Biosciences, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| EDP1815 / Evelo Biosci
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - Dec 29, 2021
P1, N=204, Completed, Sponsor: Evelo Biosciences, Inc.
Active, not recruiting --> Completed Recruiting --> Completed | N=132 --> 204 | Trial completion date: Oct 2019 --> Oct 2021 | Trial primary completion date: Oct 2019 --> Oct 2021
- ||||| EDP1815 / Evelo Biosci
New P2 trial: A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis (clinicaltrials.gov) - Nov 15, 2021
P2, N=300, Not yet recruiting, Sponsor: Evelo Biosciences, Inc.
- || EDP1867 / Evelo Biosci
Phase classification, Trial completion date, Trial primary completion date: EDP1867-101: Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma (clinicaltrials.gov) - Nov 14, 2021
P1, N=96, Recruiting, Sponsor: Evelo Biosciences, Inc.
Recruiting --> Completed | N=132 --> 204 | Trial completion date: Oct 2019 --> Oct 2021 | Trial primary completion date: Oct 2019 --> Oct 2021 Phase classification: P1a/1b --> P1 | Trial completion date: Nov 2021 --> May 2022 | Trial primary completion date: Sep 2021 --> Apr 2022
- ||| EDP1503 / Evelo Biosci
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Checkpoint inhibition, Metastases: KEYNOTE-939: A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors (clinicaltrials.gov) - Nov 12, 2021
P1/2, N=69, Completed, Sponsor: Evelo Biosciences, Inc.
Phase classification: P1a/1b --> P1 | Trial completion date: Nov 2021 --> May 2022 | Trial primary completion date: Sep 2021 --> Apr 2022 Recruiting --> Completed | N=120 --> 69 | Trial completion date: Dec 2020 --> Oct 2021 | Trial primary completion date: Dec 2020 --> Jun 2021
- ||| EDP1066 / Evelo Biosci
Trial completion, Enrollment change: A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - Nov 9, 2021
P1a/1b, N=114, Completed, Sponsor: Evelo Biosciences, Inc.
Recruiting --> Completed | N=120 --> 69 | Trial completion date: Dec 2020 --> Oct 2021 | Trial primary completion date: Dec 2020 --> Jun 2021 N=168 --> 114 | Active, not recruiting --> Completed
- | EDP1815 / Evelo Biosci
Enrollment change, Trial termination: Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection (clinicaltrials.gov) - Nov 5, 2021
P2, N=16, Terminated, Sponsor: Evelo Biosciences, Inc.
N=168 --> 114 | Active, not recruiting --> Completed N=60 --> 16 | Recruiting --> Terminated; Insufficient study defined patient population
- || EDP1815 / Evelo Biosci
New P1 trial: Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms (clinicaltrials.gov) - Oct 3, 2021
P1, N=24, Recruiting, Sponsor: Evelo Biosciences, Inc.
- EDP1867 / Evelo Biosci
[VIRTUAL] Oral delivery of non-live preparation of Veillonella parvula modulates CNS inflammation via the small intestinal axis: a novel approach to treating neuroinflammatory diseases (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2212;
This is a striking finding that suggests a new pathway of biological control of neuroinflammation and type of medicine for its treatment. The efficacy of this non-live bacterial product is evidence that this is a result of a direct pharmacological interaction with host cells in the gut and is not the result of modification of the gut microbiota.
- EDP1867 / Evelo Biosci
[VIRTUAL] Oral delivery of non-live preparation of Veillonella parvula modulates CNS inflammation via the small intestinal axis: a novel approach to treating neuroinflammatory diseases (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_866;
This is a striking finding that suggests a new pathway of biological control of neuroinflammation and type of medicine for its treatment. The efficacy of this non-live bacterial product is evidence that this is a result of a direct pharmacological interaction with host cells in the gut and is not the result of modification of the gut microbiota.
- | EDP1503 / Evelo Biosci, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Trial suspension, Trial primary completion date, Metastases: Pembrolizumab and EDP1503 in Advanced Melanoma (clinicaltrials.gov) - Jun 30, 2021
P2, N=8, Suspended, Sponsor: University of Chicago
The efficacy of this non-live bacterial product is evidence that this is a result of a direct pharmacological interaction with host cells in the gut and is not the result of modification of the gut microbiota. N=70 --> 8 | Active, not recruiting --> Suspended | Trial primary completion date: Nov 2021 --> Nov 2022
- ||| EDP1867 / Evelo Biosci
New P1 trial: EDP1867-101: Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma (clinicaltrials.gov) - Jun 15, 2021
P1a/1b, N=96, Recruiting, Sponsor: Evelo Biosciences, Inc.
- EDP2939 / Evelo Biosci
[VIRTUAL] Orally-delivered microbial extracellular vesicle induces anti-inflammatory activity in mice () - May 19, 2021 - Abstract #IMMUNOLOGY2021IMMUNOLOGY_2333;
We now extend these observations to EDP2939, a bacterial extracellular vesicle (EV), that has potent anti-inflammatory activity in preclinical models...EVs are particularly effective at engaging host cells in the gut to modulate distal inflammation. These data point to oral EVs as a new class of immunotherapeutic drugs.
- EDP1908 / Evelo Biosci
[VIRTUAL] Oral delivery of a microbial extracellular vesicle induces potent anti-tumor immunity in mice () - May 19, 2021 - Abstract #IMMUNOLOGY2021IMMUNOLOGY_2218;
These data point to oral EVs as a new class of immunotherapeutic drugs that harness the biology of the small intestinal axis, acting locally on host cells in the gut to control distal immune responses within the TME. EDP1908 is in preclinical development for the treatment of cancer.
- EDP1908 / Evelo Biosci
[VIRTUAL] Oral delivery of a microbial extracellular vesicle induces potent anti-tumor immunity in mice () - May 19, 2021 - Abstract #IMMUNOLOGY2021IMMUNOLOGY_550;
These data point to oral EVs as a new class of immunotherapeutic drugs that harness the biology of the small intestinal axis, acting locally on host cells in the gut to control distal immune responses within the TME. EDP1908 is in preclinical development for the treatment of cancer.
- EDP1815 / Evelo Biosci, Abdul Latif Jameel Health
ATOPIC DERMATITIS PHASE 1B POSITIVE TRIAL RESULTS FOR EDP1815, AN ORAL SINGLESTRAIN COMMENSAL MICROBE () - Apr 23, 2021 - Abstract #ISAD2021ISAD_151;
At the day 70 follow-up, the percentage of patients receiving EDP1815 achieving EASI50 was 44% compared with 0% in the placebo group; and the proportion achieving an IGA score of 0 or 1 was 31%, again compared with 0% in the placebo group. The phase 1b clinical data presented provide proof of concept for further clinical development of EDP1815 in the treatment of atopic dermatitis.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, EDP1815 / Evelo Biosci
Trial completion date, Trial primary completion date: TACTIC-E: mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (clinicaltrials.gov) - Mar 19, 2021
P2/3, N=1407, Recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
The phase 1b clinical data presented provide proof of concept for further clinical development of EDP1815 in the treatment of atopic dermatitis. Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
- ||| EDP1815 / Evelo Biosci
Enrollment closed: A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis (clinicaltrials.gov) - Feb 10, 2021
P2, N=225, Active, not recruiting, Sponsor: Evelo Biosciences, Inc.
Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Feb 2021 --> Feb 2022 Recruiting --> Active, not recruiting
- || EDP1815 / Evelo Biosci
Trial completion date, Trial primary completion date: Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection (clinicaltrials.gov) - Jan 31, 2021
P2, N=60, Recruiting, Sponsor: Evelo Biosciences, Inc.
Recruiting --> Active, not recruiting Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Dec 2020 --> Jul 2021
- ||||| EDP1815 / Evelo Biosci
New P2 trial: A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis (clinicaltrials.gov) - Oct 25, 2020
P2, N=225, Recruiting, Sponsor: Evelo Biosciences, Inc.